Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H19F2N5O2 |
Molecular Weight | 399.394 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@H]1C2CCC(CC2)[C@@H]1NC3=NC(=NC=C3F)C4=CNC5=NC=C(F)C=C45
InChI
InChIKey=JGPXDNKSIXAZEQ-SBBZOCNPSA-N
InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
Molecular Formula | C20H19F2N5O2 |
Molecular Weight | 399.394 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P03427 Gene ID: NA Gene Symbol: PB2 Target Organism: Influenza A virus (strain A/Wilson-Smith/1933 H1N1) (Influenza A virus|||(strain A/WS/1933 H1N1)) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27451344 |
|||
Target ID: CHEMBL612610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25019388 |
0.32 nM [EC50] | ||
Target ID: CHEMBL262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25019388 |
1.6 µM [Ki] |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. | 2014 Aug 14 |
|
JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. | 2016 Sep |
|
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza. | 2017 Feb 9 |
|
Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. | 2018 |
|
Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers. | 2018 Nov |
|
Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. | 2019 Mar 15 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:41:58 GMT 2023
by
admin
on
Fri Dec 15 16:41:58 GMT 2023
|
Record UNII |
DFC121MXC3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DFC121MXC3
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
C158086
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
100000174647
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
Pimodivir
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
C170320
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
ALTERNATIVE | |||
|
10321
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
67286591
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
EF-35
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
DB14974
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
DTXSID801028095
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY | |||
|
1629869-44-8
Created by
admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Vertex Pharmaceuticals; Developer: Janssen Pharmaceuticals, Vertex Pharmaceuticals; Class: Antiviral; Mechanism of Action: Viral protein inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase II for Influenza A virus infections; Most Recent Events: 01 Jun 2016 Janssen Research and Development completes a pharmacokinetics phase I trial in Healthy volunteers in USA and Belgium (PO) (NCT02652650), 01 Apr 2016 Janssen Research and Development completes a bioavailability phase I trial in Healthy volunteers in Belgium (PO) (NCT02659735), 01 Apr 2016 Janssen Research & Development completes a phase I trial in Healthy volunteers in Belgium (NCT02658825)
|